
Spero Therapeutics, Inc. – NASDAQ:SPRO
Spero Therapeutics stock price today
Spero Therapeutics stock price monthly change
Spero Therapeutics stock price quarterly change
Spero Therapeutics stock price yearly change
Spero Therapeutics key metrics
Market Cap | 52.55M |
Enterprise value | N/A |
P/E | -1.27 |
EV/Sales | -24.97 |
EV/EBITDA | 1.46 |
Price/Sales | 0.01 |
Price/Book | N/A |
PEG ratio | -0.02 |
EPS | 0.43 |
Revenue | 102.29M |
EBITDA | 16.08M |
Income | 23.40M |
Revenue Q/Q | 468.10% |
Revenue Y/Y | 108.67% |
Profit margin | -1786.12% |
Oper. margin | -1662.46% |
Gross margin | 21.86% |
EBIT margin | -1662.46% |
EBITDA margin | 15.73% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSpero Therapeutics stock price history
Spero Therapeutics stock forecast
Spero Therapeutics financial statements
Jun 2023 | 788K | -11.91M | -1511.93% |
---|---|---|---|
Sep 2023 | 25.47M | -3.20M | -12.58% |
Dec 2023 | 71.82M | 51.19M | 71.27% |
Mar 2024 | 4.20M | -12.66M | -301.36% |
Mar 2024 | 4.20M | -12.66M | -301.36% |
---|---|---|---|
Sep 2025 | 13M | -13.01M | -100.09% |
Oct 2025 | 10.5M | -20.87M | -198.8% |
Dec 2025 | 25M | -13.91M | -55.66% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 98885000 | 44.10M | 44.6% |
---|---|---|---|
Sep 2023 | 107101000 | 53.39M | 49.86% |
Dec 2023 | 182390000 | 75.49M | 41.39% |
Mar 2024 | 167703000 | 71.45M | 42.61% |
Jun 2023 | -18.56M | 0 | 0 |
---|---|---|---|
Sep 2023 | 15.91M | 0 | 220K |
Dec 2023 | -17.49M | 0 | 1K |
Mar 2024 | 5.93M | 0 | 0 |
Spero Therapeutics alternative data
Aug 2023 | 35 |
---|---|
Sep 2023 | 35 |
Oct 2023 | 35 |
Nov 2023 | 35 |
Dec 2023 | 35 |
Jan 2024 | 35 |
Feb 2024 | 35 |
Mar 2024 | 46 |
Apr 2024 | 46 |
May 2024 | 46 |
Jun 2024 | 46 |
Jul 2024 | 46 |
Spero Therapeutics other data
Period | Buy | Sel |
---|---|---|
Aug 2023 | 0 | 18765 |
Sep 2023 | 0 | 39496 |
Feb 2024 | 0 | 229741 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | SHUKLA SATH director, officer: CEO and Pres.. | Common Stock | 45,093 | $1.45 | $65,385 | ||
Sale | HAMED KAMAL officer: Chief Medical Officer | Common Stock | 28,075 | $1.37 | $38,463 | ||
Sale | KEUTZER TIMOTHY officer: Chief Operating Officer | Common Stock | 30,971 | $1.36 | $42,121 | ||
Sale | MAHADEVIA ANKIT director | Common Stock | 63,795 | $1.37 | $87,399 | ||
Sale | JOSEPH TAMARA L officer: Chief Legal Officer | Common Stock | 30,906 | $1.37 | $42,341 | ||
Sale | SHUKLA SATH director, officer: CEO and Pres.. | Common Stock | 30,901 | $1.37 | $42,334 | ||
Sale | HAMED KAMAL officer: Chief Medical Officer | Common Stock | 39,496 | $1.27 | $50,160 | ||
Sale | SHUKLA SATH director, officer: CEO and Pres.. | Common Stock | 4,163 | $1.3 | $5,412 | ||
Sale | KEUTZER TIMOTHY officer: Chief Development Offi.. | Common Stock | 1,854 | $1.26 | $2,336 | ||
Sale | JOSEPH TAMARA L officer: Chief Legal Officer | Common Stock | 1,854 | $1.26 | $2,336 |
Patent |
---|
Application Filling date: 12 Nov 2021 Issue date: 12 May 2022 |
Application Filling date: 25 Jun 2019 Issue date: 12 Aug 2021 |
Application Filling date: 25 Jan 2021 Issue date: 22 Jul 2021 |
Application TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE Filling date: 29 Dec 2020 Issue date: 29 Apr 2021 |
Application TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE Filling date: 6 Feb 2018 Issue date: 20 Feb 2020 |
Application Filling date: 15 Dec 2017 Issue date: 16 Jan 2020 |
Quarter | Transcript |
---|---|
Q4 2023 13 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
Q1 2023 11 May 2023 | Q1 2023 Earnings Call Transcript |
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK
Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market
Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
-
What's the price of Spero Therapeutics stock today?
One share of Spero Therapeutics stock can currently be purchased for approximately $1.84.
-
When is Spero Therapeutics's next earnings date?
Unfortunately, Spero Therapeutics's (SPRO) next earnings date is currently unknown.
-
Does Spero Therapeutics pay dividends?
No, Spero Therapeutics does not pay dividends.
-
How much money does Spero Therapeutics make?
Spero Therapeutics has a market capitalization of 52.55M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 99.13% to 96.74M US dollars.
-
What is Spero Therapeutics's stock symbol?
Spero Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SPRO".
-
What is Spero Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Spero Therapeutics?
Shares of Spero Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Spero Therapeutics's key executives?
Spero Therapeutics's management team includes the following people:
- Dr. Ankit Mahadevia M.D., MBA Co-Founder, Chief Executive Officer, Pres & Director(age: 44, pay: $966,830)
- Dr. David A. Melnick M.D. Chief Medical Officer(age: 73, pay: $647,310)
- Ms. Cristina Larkin Chief Operating Officer(age: 55, pay: $639,360)
-
Is Spero Therapeutics founder-led company?
Yes, Spero Therapeutics is a company led by its founder Dr. Ankit Mahadevia M.D., MBA.
-
How many employees does Spero Therapeutics have?
As Jul 2024, Spero Therapeutics employs 46 workers.
-
When Spero Therapeutics went public?
Spero Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 2 Nov 2017.
-
What is Spero Therapeutics's official website?
The official website for Spero Therapeutics is sperotherapeutics.com.
-
Where are Spero Therapeutics's headquarters?
Spero Therapeutics is headquartered at 675 Massachusetts Avenue, Cambridge, MA.
-
How can i contact Spero Therapeutics?
Spero Therapeutics's mailing address is 675 Massachusetts Avenue, Cambridge, MA and company can be reached via phone at 857 242 1600.
Spero Therapeutics company profile:

Spero Therapeutics, Inc.
sperotherapeutics.comNASDAQ
46
Biotechnology
Healthcare
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02139
CIK: 0001701108
ISIN: US84833T1034
CUSIP: 84833T103